We are live on ! Find out more
BCLSI

Bain Capital Life Sciences Investors Portfolio holdings

AUM $1.11B
1-Year Est. Return 171.34%
This Fund
S&P 500
This Quarter Est. Return
+9.6%
1 Year Est. Return
+171.34%
3 Year Est. Return
+643.23%
5 Year Est. Return
+451.99%
10 Year Est. Return
–
AUM
$961M
AUM Growth
+$50.3M
Cap. Flow
+$3.74M
Cap. Flow %
0.39%
Top 10 Hldgs %
89.37%
Holding
26
New
1
Increased
5
Reduced
1
Closed
2

Top Buys

Rank Stock Value
1
CDTX
Cidara Therapeutics
CDTX
+$8.44M
2
CABA icon
Cabaletta Bio
CABA
+$6.43M
3
XLO icon
Xilio Therapeutics
XLO
+$685K
4
MRNS
Marinus Pharmaceuticals, Inc
MRNS
+$594K
5
ANNX icon
Annexon
ANNX
+$3.2K

Top Sells

Rank Stock Value
1
ARQT icon
Arcutis Biotherapeutics
ARQT
+$9.59M
2
TNGX icon
Tango Therapeutics
TNGX
+$1.72M
3
ACRS icon
Aclaris Therapeutics
ACRS
+$1.1M

Sector Composition

Rank Sector Weight
1 Healthcare 99.43%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NUVL
1
DELISTED
Nuvalent
NUVL
$276M 28.71%
2,697,267
– –
NAMS icon
2
NewAmsterdam Pharma
NAMS
$3.31B
$174M 18.09%
10,473,913
– –
IRON icon
3
Disc Medicine
IRON
$2.99B
$88.2M 9.18%
1,795,735
– –
DNTH icon
4
Dianthus Therapeutics
DNTH
$6.12B
$82.5M 8.58%
3,013,423
– –
SVRA icon
5
Savara
SVRA
$1.19B
$61.8M 6.43%
14,565,457
– –
PHVS icon
6
Pharvaris
PHVS
$2.39B
$61.2M 6.37%
3,303,381
– –
ANNX icon
7
Annexon
ANNX
$895M
$50M 5.2%
8,449,748
+540
+0% +$3.2K
SLDB icon
8
Solid Biosciences
SLDB
$905M
$28.1M 2.93%
4,034,582
– –
TNGX icon
9
Tango Therapeutics
TNGX
$4.5B
$20.9M 2.17%
2,712,008
-180,655
-6% -$1.72M
KYTX icon
10
Kyverna Therapeutics
KYTX
$491M
$16.5M 1.71%
3,368,370
– –
MRSN
11
DELISTED
Mersana Therapeutics
MRSN
$16.4M 1.7%
346,547
– –
CABA icon
12
Cabaletta Bio
CABA
$455M
$13M 1.36%
2,760,888
+1,110,924
+67% +$6.43M
XFOR icon
13
X4 Pharmaceuticals
XFOR
$448M
$11.3M 1.18%
563,859
– –
IPSC icon
14
Century Therapeutics
IPSC
$361M
$9.25M 0.96%
5,410,361
– –
AVIR icon
15
Atea Pharmaceuticals
AVIR
$407M
$8.33M 0.87%
2,485,638
– –
CDTX
16
DELISTED
Cidara Therapeutics
CDTX
$7.56M 0.79%
+703,080
New +$8.44M
RPID icon
17
Rapid Micro Biosystems
RPID
$87.7M
$7.51M 0.78%
8,434,560
– –
CCCC icon
18
C4 Therapeutics
CCCC
$406M
$6.34M 0.66%
1,111,910
– –
SYRS
19
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$5.91M 0.62%
2,750,151
+343
+0% +$1.23K
NAUT icon
20
Nautilus Biotechnolgy
NAUT
$115M
$5.7M 0.59%
2,000,000
– –
MRNS
21
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$4.74M 0.49%
2,693,380
+425,700
+19% +$594K
XLO icon
22
Xilio Therapeutics
XLO
$59.2M
$3.6M 0.37%
326,201
+55,812
+21% +$685K
IVVD icon
23
Invivyd
IVVD
$205M
$1.84M 0.19%
1,799,595
– –
NAMSW icon
24
NewAmsterdam Pharma Warrant
NAMSW
$82.8M
$700K 0.07%
100,000
– –
ACRS icon
25
Aclaris Therapeutics
ACRS
$841M
– –
-1,000,000
Closed -$1.1M
1
2

Similar funds

SL
Sentinus LLC Oak Brook, Illinois $1.11B AUM 17.13% 1-Year Est. Return
JTWM
Jackson Thornton Wealth Management Montgomery, Alabama $1.11B AUM 22.53% 1-Year Est. Return
RWM
RKL Wealth Management Lancaster, Pennsylvania $1.11B AUM 18.99% 1-Year Est. Return
EIA
Emerald Investment Advisers Leola, Pennsylvania $1.11B AUM
HH
Hilltop Holdings Dallas, Texas $1.11B AUM 24.7% 1-Year Est. Return
RIM
Rockbridge Investment Management Syracuse, New York $1.11B AUM 13.62% 1-Year Est. Return
YL
YCG LLC Austin, Texas $1.1B AUM 4.87% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Bain Capital Life Sciences Investors's Q3 2024 Portfolio in Review

As of Q3 2024, Bain Capital Life Sciences Investors held 26 positions worth $961M, up 5.5% from $911M the previous quarter. Its ten largest holdings account for 89% of the portfolio.

Bain Capital Life Sciences Investors's Q3 2024 filing shows 1 new, 5 increased, 1 reduced and 2 closed positions. Its largest new stake was Cidara Therapeutics: 703,080 shares worth $7.56M. The largest sale was Arcutis Biotherapeutics, an estimated $9.59M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier.

  • Bain Capital Life Sciences Investors's largest Q3 2024 buy was Cidara Therapeutics: 703,080 shares worth $7.56M.
  • Bain Capital Life Sciences Investors added most to Cabaletta Bio in Q3 2024, an estimated $6.43M increase.
  • Bain Capital Life Sciences Investors's biggest Q3 2024 reduction was Tango Therapeutics, cutting an estimated $1.72M.
  • Bain Capital Life Sciences Investors fully exited Arcutis Biotherapeutics in Q3 2024, selling an estimated $9.59M.
  • Bain Capital Life Sciences Investors's ten largest holdings make up 89% of its $961M portfolio in Q3 2024.
  • Bain Capital Life Sciences Investors opened 1 new position and closed 2 in Q3 2024.
  • Bain Capital Life Sciences Investors's portfolio value rose 5.5% quarter-over-quarter to $961M.

Based on Bain Capital Life Sciences Investors's 13F filing for Q3 2024, filed 14 Nov 2024.